News|Articles|January 1, 2026

Top 5 dermatology articles of 2025

Author(s)MHE Staff
Listen
0:00 / 0:00

Key Takeaways

  • Semaglutide, a GLP-1 drug, is potentially linked to allodynia, a rare painful skin sensitivity condition, according to recent research.
  • Climate change and air pollution are increasingly associated with worsening atopic dermatitis, affecting up to 15% of the global population.
SHOW MORE

New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.

  1. Study Links Semaglutide to Rare Skin Pain Condition
    New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug semaglutide and allodynia, a painful skin sensitivity.
    Read more
  2. Higher Air Pollution and Extreme Weather Linked to Adult Atopic Dermatitis
    Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic dermatitis (AD), the most common chronic inflammatory skin condition, affecting up to 15% of people worldwide.
    Read more
  3. Regenerative Medicine Offers Positive Results for Treating Vitiligo
    Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.
    Read more
  4. Combined Oral and Phototherapy Treatments Show Promise in Treating Severe Vitiligo
    In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.
    Read more
  5. Opzelura Topical Cream Drives Incyte's Record Growth in 2024 with 50% Revenue Surge
    Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.
    Read more


Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME